PAREXEL?s NORTH AMERICAN MEDICAL SERVICES DIVISION EXPANDS ITS THERAPEUTIC TEAM
BOSTON, MA, April 17, 2001 — PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest Contract Research and Medical Marketing Services Organizations, today announced the addition of three new scientific leaders to their North American Medical Services Division (NAMS). Wayne Dankner, M.D. will serve as a Medical Director in PAREXEL’s Research Triangle Park (RTP) office, located in Chapel Hill, NC. Cynthia Romerdahl, Ph.D. joins NAMS as Principal Scientist and Director of Oncology at the Waltham headquarters office. Steven Balyakin, M.D., Ph.D. joins PAREXEL as a Medical Director in PAREXEL’s San Diego office.
“Wayne, Cynthia, and Steve bring a combined 65 years of scientific research and strategic medical experience to PAREXEL. The addition of these specialists will further enhance our reputation in the key areas of oncology, immunology, and infectious disease,” stated Warren Stern, Ph.D., Senior Vice President of PAREXEL’s Scientific and Medical Services Unit.
Following his residency at Stanford University Hospital’s Department of Pediatrics and subsequent fellowship and faculty appointment at University of California-San Diego, where he was an Associate Professor of Pediatrics, Dr. Dankner established himself as a prominent practitioner in pediatric studies. As an authority on Pediatrics and Infectious Diseases, currently he is a Fellow of the American Academy of Pediatrics and also is an active member of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society for Pediatric Research. He has contributed heavily to the development and conduct of pediatric HIV studies through the NIH-supported Pediatric AIDS Clinical Trials Group. He will use his infectious disease experience to augment PAREXEL’s reputation in the development of treatments for AIDS and other important infections that challenge the medical community at present.
In addition to Dankner, PAREXEL gains Dr. Cynthia Romerdahl as another scientific resource. Dr. Romerdahl brings a in depth knowledge of drug discovery programs and pre-clinical evaluation of novel therapeutics for cancer. Her training began at Washington State University, where she received her B.S. in Bacteriology and Public Health, and continued at the University of California-Berkeley, where she received her Ph.D. in Molecular Biology.
Dr. Romerdahl is a member of both the American Association for Cancer Research and Women in Cancer Research. She is also widely involved in U.S. patent applications and established a new course in cell biology/biochemistry at the University of Puget Sound in Tacoma, WA, where she was named Visiting Assistant Professor of Biology. She most recently directed oncology research programs for six years at BASF Bioresearch Corporation before joining PAREXEL, where she will apply her extensive knowledge of oncology drug development for the benefit of PAREXEL’s clients.
Dr. Steven Balyakin is the most recently installed scientific expert in NAMS. Dr. Balyakin possesses twenty years of clinical expertise in both academic and practice settings. He brings to PAREXEL over fifteen years of solid experience in the pharmaceutical industry, both in the US and internationally, including clinical and post-marketing safety.
A graduate of Vladivostok State Medical School in Russia, Dr. Balyakin completed his fellowship and Ph.D. in Pulmonary and Allergic Diseases at the Moscow Second State Medical School, where he later served as an Associate Professor of Medicine. Prior to joining NAMS, Dr. Balyakin held various medical and drug safety positions at MTRA, Searle and PPD. Most recently, he served as Senior Medical Director and Chief Safety Officer at Alliance Pharmaceutical Corporation. Bilingual in Russian and English, Steve counts over twenty-five professional journal articles to his credit.
“Through their progressive research expertise and ties to academia, Drs. Dankner, Romerdahl, and Balyakin are strong additions to the Medical group,” notes Jonathan M. Fishbein, M.D., Vice President of North American Medical Services. “We in Medical Services are convinced that bringing such seasoned individuals into the PAREXEL community will enhance the scientific capability of our organization.”
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its newest subsidiary, Perceptive
Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 47 locations throughout 29 countries around the world, and has approximately 4,350 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended December 31, 2000.